MedPal AI raises 5 million pounds despite share price decline following strategic fundraise

Shares in MedPal AI plc declined by 10% to 3.6 pence on Friday following the announcement that the digital health and artificial intelligence company had successfully raised £5 million through a placing of new ordinary shares. The share price movement occurred despite the placing being priced at 3.5 pence per share, representing a significant 40% premium to the 2.5 pence at which the company secured £3 million during its April fundraising round.

The issue price reflected a 12.5% discount to the previous day’s closing price of 4 pence, a pricing structure that frequently exerts short-term downward pressure on equity valuations even when the underlying transaction signals management confidence in longer-term prospects.

The company has earmarked up to £500,000 of the proceeds for the acquisition of Solid State Technologies, a profitable software enterprise specialising in electronic medicines administration records. These digital systems provide the technological infrastructure required to track pharmaceutical products administered to patients at the point of care. MedPal stated that the transaction would complete a closed-loop platform for care homes, integrating prescribing, dispensing, administration and reconciliation functions within a single technological ecosystem.

According to management accounts for the period ending May, Solid State Technologies generated annualised revenue of approximately £843,000 alongside annualised profit of roughly £307,000. The acquisition therefore brings both revenue generation and operational profitability to the enlarged group.

A substantially larger allocation of up to £3 million will fund inventory procurement and patient acquisition initiatives ahead of the United Kingdom launch of the first oral GLP-1 weight-loss pharmaceutical, oral Wegovy, scheduled for 6 July. GLP-1 drugs function by mimicking a naturally occurring hormone that regulates both appetite and blood sugar levels, contributing to the substantial surge in demand for weight-loss treatments across developed markets.

MedPal operates a weight-loss clinic and maintains a supply relationship with Novo Nordisk, the manufacturer of Wegovy. The company aims to secure a substantial patient cohort from the initial launch phase. Management cited United States market data indicating that prescription volumes exceeded three million during the five months following the pill’s January launch in that jurisdiction, with more than 80% of prescriptions issued to patients previously unexposed to GLP-1 therapy. The company forecasts that each active private patient will generate approximately £2,400 in recurring annual revenue.

The balance of the fundraising proceeds will provide working capital to support what the company characterised as record National Health Service dispensing volumes processed through its robotic distribution hub. This infrastructure investment appears designed to capitalise on growing demand within the publicly funded healthcare sector.

MedPal has appointed Erin Fox as senior director of marketing to oversee patient acquisition for the upcoming launch. Fox previously served as head of global digital at Avolta, the duty-free retail operator, bringing consumer-facing digital marketing expertise to the medical technology sector.

Chief Executive Jason Drummond characterised the fundraising, which was priced at a premium to the April placing, as an endorsement of the company’s operational progress and the commercial opportunities currently available to the business.